Study Description
The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to standard of care (SOC) to induce and maintain remission in study participants with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), when used in combination with rituximab (RTX) induction. The trial will also assess the impact of iptacopan on disease relapses, evolution of renal function and proteinuria, GC side effects, patients' immune status, and QoL. This is a randomized, controlled study to evaluate the efficacy and safety of iptacopan in combination with RTX induction therapy for the treatment of newly diagnosed or relapsed patients with active GPA or MPA.
Interventions
Iptacopan
Placebo
Rituximab
Eligibility Criteria
Inclusion Criteria:
* Newly diagnosed or relapsed GPA and MPA (according to the 2022 ACR/EULAR classification criteria for GPA and MPA) requiring treatment with RTX and GC as per investigator's judgement.
* BVAS assessment with ≥1 major item, or ≥3 minor items, or ≥2 renal items at Screening.
* Positive antibody test for anti-proteinase 3 (PR3) or anti-myeloperoxidase (MPO) antibodies at Screening or with history of documented evidence of a positive antibody test.
Exclusion Criteria:
* Other systemic disease which constitutes the primary illness, including but not limited to: eosinophilic granulomatosis with polyangiitis (EGPA), moderate to severe systemic lupus erythematosus, IgA vasculitis (Purpura Schönlein-Henoch), rheumatoid vasculitis, Sjögren's syndrome, anti-glomerular basement membrane (GBM) disease, cryoglobulinemic vasculitis, autoimmune hemolytic anemia, autoimmune lymphoproliferative syndrome or mixed connective tissue disease.
* Alveolar hemorrhage requiring invasive pulmonary ventilation support at Screening.
* Severe kidney disease defined as estimated glomerular filtration rate (eGFR) \<15 mL/minute/1.73m2, or kidney failure defined as receiving renal replacement therapy such as hemo(dia)filtration, hemo-/peritoneal dialysis, or having received a kidney transplant.
* Received plasma exchange/-pheresis within 12 weeks prior to Screening.
Novartis Investigative Site
Recruiting
Caba,Buenos Aires,C1180aax,Argentina
Novartis Investigative Site
Recruiting
Caba,Buenos Aires,C1181ach,Argentina
Novartis Investigative Site
Recruiting
La Plata,Buenos Aires,B1900awt,Argentina
Novartis Investigative Site
Recruiting
Westmead,New South Wales,2145,Australia
Novartis Investigative Site
Recruiting
Adelaide,South Australia,5000,Australia
Novartis Investigative Site
Recruiting
Clayton,Victoria,3168,Australia
Novartis Investigative Site
Recruiting
Concord,New South Wales,2139,Australia
Novartis Investigative Site
Recruiting
Graz,8036,Austria
Novartis Investigative Site
Recruiting
Wien,1090,Austria
Novartis Investigative Site
Recruiting
Fleurimont,Quebec,J1h 5n4,Canada
Novartis Investigative Site
Recruiting
Montreal,Quebec,H2x 1r9,Canada
Novartis Investigative Site
Recruiting
Montreal,Quebec,H4j 1c5,Canada
Novartis Investigative Site
Recruiting
Quebec,G1r 2j6,Canada
Novartis Investigative Site
Recruiting
London,Ontario,N6a 5w9,Canada
Novartis Investigative Site
Recruiting
Shijiazhuang,Hebei,050000,China
Novartis Investigative Site
Recruiting
Beijing,100034,China
Novartis Investigative Site
Recruiting
Zhengzhou,Henan,450052,China
Novartis Investigative Site
Recruiting
Shanghai,Shanghai,200032,China
Novartis Investigative Site
Recruiting
Praha,12808,Czechia
Novartis Investigative Site
Recruiting
Aarhus N,8200,Denmark
Novartis Investigative Site
Recruiting
Copenhagen,Dk-2100,Denmark
Novartis Investigative Site
Recruiting
Herlev,Dk-2730,Denmark
Novartis Investigative Site
Recruiting
Marseille,13385,France
Novartis Investigative Site
Recruiting
Paris,75014,France
Novartis Investigative Site
Recruiting
Toulouse 4,31054,France
Novartis Investigative Site
Recruiting
Angers Cedex 9,49933,France
Novartis Investigative Site
Recruiting
Brest,29200,France
Novartis Investigative Site
Recruiting
Dijon,21034,France
Novartis Investigative Site
Recruiting
Berlin,13353,Germany
Novartis Investigative Site
Recruiting
Kirchheim,73230,Germany
Novartis Investigative Site
Recruiting
Muenchen,81377,Germany
Novartis Investigative Site
Recruiting
Budapest,1023,Hungary
Novartis Investigative Site
Recruiting
Debrecen,4032,Hungary
Novartis Investigative Site
Recruiting
Szeged,6720,Hungary
Novartis Investigative Site
Recruiting
Plasencia,Extremadura,10600,Spain
Novartis Investigative Site
Recruiting
Pamplona,Navarra,31008,Spain
Novartis Investigative Site
Recruiting
Madrid,28046,Spain
Novartis Investigative Site
Recruiting
Ankara,06230,Turkey
Novartis Investigative Site
Recruiting
Ankara,06500,Turkey
Novartis Investigative Site
Recruiting
Pendik Istanbul,34899,Turkey
Arizona Arthritis and Rheumatology Research PLLC
Recruiting
Mesa,Arizona,85202,United States
Mandee Lochridge
Areena Swarup
Mayo Clinic Rochester
Recruiting
Rochester,Minnesota,55905,United States
Ulrich Specks
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.